Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation

Journal of Heart and Lung Transplantation

Volumn 19, Issue 6, 2000, Pages 529-537

  Keogh, Anne ^a   MacDonald, Peter ^a   Kaan, Annemarie ^a   Aboyoun, Christina ^a   Spratt, Phillip ^a   Mundy, Julie ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHOLESTEROL; COTRIMOXAZOLE; CYCLOSPORIN; DILTIAZEM; GANCICLOVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; PREDNISOLONE; RANITIDINE; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTERY INTIMA PROLIFERATION; ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT REJECTION; HEADACHE; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; MYOSITIS; PRIORITY JOURNAL; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT OUTCOME;

CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; CORONARY VESSELS; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PRAVASTATIN; SAFETY; SIMVASTATIN; SURVIVAL RATE; TREATMENT OUTCOME; TUNICA INTIMA;

EID: 0034123276     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(00)00077-2     Document Type: Article

References (26)

1. Sacks F., Pfeffer M., Moye L., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels (CARE). New Engl J Med. 335:1996;1001-1009.
2. Randomised trial of cholesterol lowering in 444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
4. Shepherd J., Cobbe S., Ford I., et al. Prevention of coronary heart disease in men with hypercholesterolemia (WOSCOPS). N Engl J Med. 333:1995;1301-1307.
5. Johnson M. Transplant coronary artery disease: non immunologic risk factors. J Heart Lung Transplant 1992;11:S124:32.
6. Keogh A., Kaan A. The Australian Cardiothoracic Organ Transplant Registry first report 1984-1992 . Aust N Z J Med. 22:1992;712-717.
7. Kobashigawa J., Katznelson S., Laks H., et al. Effect of pravastatin in outcomes after cardiac transplantation. N Engl J Med. 333:1995;621-627.
8. Wenke K., Meiser B., Thiery J., et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation - a four year randomised trial. Circulation. 96:1997;1398-1402.
9. Wenke K., Thiery J., Meiser B., Arndtz N., Seidel D., Reichart B. Long term simvastatin therapy for hypercholesterolemia in heart transplant recipients. Z Cardiol. 84:1995;130-136.
10. Keogh A., Simons L., Spratt P., et al. Hyperlipidemia following cardiac transplantation. J Heart Transplant. 7:1988;171-175.
11. Bilheimer D. Long term tolerance of lovastatin and simvastatin. Cardiology. 77:(suppl 4):1990;58-65.
12. Vanhaecke J., Cleemput J., Van Lierde J., Daenen W., De Geest H. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation. 58:1994;42-45.
13. Kobashigawa J, Murphy F, Stevenson L, et al. Low dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990;82(suppl IV):IV-281.
14. Christans U., Jacobsen W., Floren L. Metabolism and drug interactions of 3-hydroxyl-3-methyl-glutaryl coenzyme A reductase inhibitors in transplant patients are the statins mechanistically similar? Pharmacol Ther. 80:1998;1-34.
15. Kleim V., Wanner C., Eisenhauer T., et al. Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine. Transplant Proc. 28:1996;3126-3128.
16. Olbricht C., Wanner C., Eisenhauer T., et al. Accumulation of lovastatin, but not pravastatin in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharm Ther. 62:1997;311-321.
17. Arnadootir M., Eriksson L., Thysell H., Karkas J. Plasma concentration profiles of simvastatin 3-hydroxyl-3-methyl-glutaryl coenzyme A reductase inhibitor activity in kidney transplant recipients with and without cyclosporine. Nephron. 65:1993;410-413.
18. Gadbut A., Caruso A., Galper J. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. J Mol Cell Cardiol. 27:1995;2397-2402.
19. Kobashigawa J., Moriguchi J., Sabad A., et al. Cyclosporine and pravastatin pharmacokinetics in cardiac transplant recipients. (abstract) J Heart Lung Transplant. 16:1997;84.
20. Lees R., Lees A. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med. 333:1995;664-665.
21. Horn M. Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals. Arch Dermatol. 132:1996;1254.
22. Hones P., Kafonek S., Laurora I., Hinninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin and fluvastatin in patients with hypercholesterolemia (CURVE). Am J Cardiol. 81:1998;582-587.
23. Rosenson R., Tangney C. Antiatherosclerotic properties of statins. JAMA. 279:1998;1643-1650.
24. Katznelson S., Wang X.-M., Chia D., et al. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant. 17:1998;335-340.
25. Lacoste L., Lam J. Comparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolemic coronary patients. J Am Coll Cardiol. 27:1996;413.
26. Simons L., Levis G., Simons J. Apparent discontinuation rates in patients prescribed lipid lowering drugs. Med J Aust. 164:1996;208-211.